Short answer: BPC-157 is a 15 amino acid synthetic peptide based on a sequence from human gastric juice; TB-500 is a 7 amino acid fragment of thymosin beta-4, a 43 amino acid actin-binding protein. Both rest almost entirely on animal and cell studies, neither is an authorised medicine, and both are on the 2026 WADA Prohibited List.
Disclosure: Peps & Protocols and Vitality Peps share an owner, Bobby Ambaum. Where this guide names suppliers, we put VP in anyway, scored on the same checks as everyone else, with links so you can verify every claim.
Half the gym calls them "the healing peptides" and buys them as a pair. The research does not call them anything of the sort. Here is what each one is, what was actually studied, and the grade we give the evidence.
It starts with the parent molecule. BPC-157 is a short synthetic peptide that reproduces part of a larger protein found in gastric juice. TB-500 is a synthetic fragment of thymosin beta-4, a protein inside cells that binds actin. Laboratories treat them as separate assays: Janoshik Analytical lists a BPC-157 analysis and a separate thymosin beta-4 / TB-500 analysis that states whether the full 43 amino acid chain or only a fragment was present.
| Attribute | BPC-157 | TB-500 |
|---|---|---|
| What it is | Partial sequence of a compound from human gastric juice | Fragment of thymosin beta-4, an actin-binding protein |
| Chain length | 15 amino acids, GEPPPGKPADDAGLV | 7 amino acids (residues 17 to 23); the parent protein has 43 |
| Molecular weight | About 1419 Da | About 889 Da for the fragment; about 4963 Da for the full protein |
| Models studied | Rat tendon, ligament, muscle and gut; cultured rat cells | Mostly the full protein: mouse heart, rat brain injury, cell assays |
| Human data | A 2025 review counted three small pilot studies | No controlled human trial of the fragment; full thymosin beta-4 reached early trials |
| Our evidence grade | C for healing, recovery and gut claims | C overall; D for human injury repair |
| Anti-doping | WADA S0, non-approved substances | WADA S2.3, thymosin beta-4 and derivatives |
Grade C means animal studies suggest something that has not been shown in humans. Grade D means early lab data or anecdotes only. Full grading method on our graded peptides hub.
Almost all of it is animal and cell work. A 2011 study tested BPC-157 on rat Achilles tendon explants and cultured tendon cells and reported more outgrowth, survival under oxidative stress and cell migration. A 2006 paper studied cut rat quadriceps muscle over 72 days; a 2010 paper studied cut rat knee ligament over 90 days. A 2025 review in Current Reviews in Musculoskeletal Medicine summed it up: broad preclinical support, three pilot studies in humans. Rats are not people. That gap is the whole story.
Thymosin beta-4 was studied first as a cell biology molecule, then as a repair candidate. The most cited paper, in Nature in 2004, reported that it helped heart cells migrate and survive in mice and improved heart function after an induced heart attack in mice. A 2012 review described it as a candidate for brain protection in rats after injury. That literature is about the full 43 amino acid protein, not the 7 amino acid fragment sold as TB-500. Borrowing one molecule's results for another is the most common trick in this space.
Because their animal literatures overlap on tissue and blood vessel repair themes, so shops market them as a recovery pair. Nothing published shows the combination does anything different from either alone, and there is no controlled human trial of the pair. A blend vial also fixes the ratio, and some blend reports give identity and amount but no purity per component. Check what the report actually covers.
No. Neither holds a marketing authorisation as a medicine anywhere in the EU. Austria's medicines agency BASG said on 27 May 2026 that many peptides sold online are unauthorised medicines whose sale and import into Austria are banned, and that a "research use" label is legally irrelevant once a shop's context shows human use. On the 2026 WADA Prohibited List, S0 covers non-approved substances "including but not limited to BPC-157", and S2.3 lists "Thymosin-beta-4 and its derivatives e.g. TB-500". Both are banned at all times. Country detail: Netherlands, Spain, Germany and Austria. This is general information, not legal advice.
For TB-500 the identity question is real: is it the 7 amino acid fragment the label names, or full thymosin beta-4? Only a mass result on the report answers that. For BPC-157, look for identity, measured amount and purity, and match the batch code to your vial.
Disclosure: Peps & Protocols and Vitality Peps share an owner, Bobby Ambaum. Same checks for every shop; checked 12 October 2026.
| Supplier | BPC-157 report | TB-500 report | Extra tests shown |
|---|---|---|---|
| Vitality Peps | Batch BP10-0126, February 2026, measured 12.03 mg on a 10 mg label, purity 99.705% | Batch TB410-0124, February 2026, purity 99.611% | None |
| Smart Peptides | Janoshik HPLC purity 99.96% on the current batch | Not checked | Heavy metals, endotoxin, LC-MS screening |
| Certa Peptides | September 2026, measured 12.98 mg on a 10 mg label, purity 99.944% | Not checked | Endotoxin on some lots |
| Pepspan | 5 mg vial, July 2026, purity 99.7% | 5 mg vial, September 2026, purity 98.5% | None |
| Baltic Peptides | Batch BP-BPC10-001, purity 99.4% | Not checked | None |
Where VP is strong: both compounds have a batch-coded report on one page, with measured mass printed next to the label so you can see the vial held more than stated. Where others go further: Smart Peptides shows endotoxin and heavy metal reports on BPC-157, and Certa and Pepspan show newer test dates. Our vendor checklist covers the rest.
Two grade C compounds sold as a "stack" is not a protocol. It is a rumour with a shipping label. If you are dealing with an injury, see a doctor and a physio first. If you are curious about peptides, start with your own baseline: the bloodwork guide or the 2-minute check. If you want someone to grade it, test it and run it with you, that is coaching.
The research cannot tell you. No study has compared them head to head in the same model with the same endpoints, and neither has solid human data for the uses people buy them for.
No. TB-500 is a 7 amino acid fragment; thymosin beta-4 is the full 43 amino acid protein. Most of the cited research used the full protein, so it does not transfer automatically to the fragment.
Very little. A 2025 review counted three small pilot studies. That is why we grade it C: animal studies suggest effects that have not been shown in humans.
Yes, both, at all times. BPC-157 falls under WADA S0 and TB-500 under S2.3 on the 2026 Prohibited List.
Cold, dry and dark, sealed. See our storage guide.
Education, not medical or legal advice. BPC-157 and TB-500 are not authorised medicines and are sold for laboratory research only.